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Abstract
Purpose: Breast cancer diagnosed at a younger age has aggressive biology being triple negative and high grade and 
is associated with poor prognosis.
Materials and Methods: Retrospectively data of 121 patients age 30 years or younger registered during the year 
2008 were reviewed. Data were extracted from the cancer registry department of the institute. Demographics studied 
were the age at diagnosis, gender, pregnancy or lactation association, family history of breast cancer, histopathological 
diagnosis, and stage of the disease, receptors, type of treatment, response, local recurrence, distant relapse, and survival.
Results: A total of 121 patients with age 30 years or less were included. An only a single patient was male. The 
age range was from 20 to 30 years; bilateral involvement was seen in a single patient. Almost half 50.4% (n = 61) 
patients had locally advanced disease at presentation. Pregnancy/lactation-associated breast cancer was seen in 29.8% 
(n = 36). The most common stage was Stage III (52.1%) and Stage II (33.9%). Invasive ductal carcinoma was the most 
common histology 94.2% (n = 114) of patients; triple negative was the most common molecular subtype present in 
46.3% (n = 56). Chemotherapy was received by 92.6% (n = 112), 88.4% (n = 107) patients received radiation therapy. 
Modified radical mastectomy was performed in 57% (n = 69), breast conservation surgery in 35.5% (n = 43), follow-
up period was 5 years, local recurrence was observed in 12.4% (n = 15) and cancer related deaths were 42.1% (n = 51).
Conclusions: Breast cancer in very young has very aggressive tumour biology, needs aggressive treatment with 
surgery, chemotherapy, radiation therapy and hormonal therapy.
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Introduction
Breast cancer is the most common type of cancer found 
in the female population. Breast cancer in young age 
is relatively uncommon accounting for 7% in women 
diagnosed at 40 years or younger.[1] Young age (<35) is an 
independent risk factor for breast cancer-related deaths, 
they are at higher risk of death as compared to middle 
age women.[2] Multiple studies from different centres 
and different countries show that breast cancer in young 
females presents as an aggressive disease which is difficult 
to manage and shows poor outcome in terms of survival 
when they are compared with the older patients.[3,4] 
Younger patients <35 years, even with receptors positive 
have 1.5-fold higher risks for mortality as compared to 
those above 35.[5] Tumours in young females are usually 
node positive, locally advance with negative hormonal 
status. The reason for this unusual behaviour is yet to be 
found.[6,7]
Our aim was to review the demographics, to see the 
incidence of brain metastasis, after complete treatment, 
and prognosis of breast cancer in very young females.
Materials and Methods
A total of 179 patients age 30 years or less were registered 
at our institute from January 2008 to December 2008, 
after exclusion of patients with incomplete data final 
sample size was 121. Medical records were reviewed for 
clinicians notes, medical reports, and treatment charts. 
Demographics studied were the age at diagnosis, gender, 
JOURNAL OF CANCER & ALLIED SPECIALTIES 2
ORIGINAL ARTICLE J Cancer Allied Spec 2016;2(1):4
clinical presentation, pregnancy or lactation associated, 
family history of breast cancer in a first-degree relative 
and locally advanced disease (tumour size >5 cm, nipple 
retraction, skin involvement, inflammatory features) 
histopathological diagnosis, stage of the disease, receptors, 
type of treatment, response to neoadjuvant chemotherapy, 
local recurrence, distant relapse, disease-free and overall 
survival (OS). Patients were categorised into luminal 
subgroups according to the receptors (oestrogen receptor, 
progesterone receptor and her-2 neu receptor). Disease-
free survival was calculated from the date of complete 
treatment till the locoregional recurrence, while OS was 
calculated from the date of diagnosis till the time to death. 
Neoadjuvant chemotherapy was offered to all patients with 
locally advanced disease, lymph node-positive disease and 
Stage IV disease, response to neoadjuvant chemotherapy 
was assessed clinically, radiological, pathologically as 
complete response (CR), partial response (PR) or no 
response (NR). 5 years survival was calculated using 
Kaplan– Meier survival curve. Data were analysed using 
SPSS version 19.
Results
The final sample size was 121; the age range was 
20 years–30 years with a median age of 28 years. 
Demographic characteristics are summarised in Table 1. 
Female patients were 99.1% (n = 120); only a single 
patient was male. Locally advanced disease (tumour size 
>5 cm, skin involvement and clinically lymph nodes 
node-positive disease) was present in 50.4% (n = 61) 
patients, 76.8% (n = 93) patients had nodal metastasis 
at presentation while 28 (23.1%) of patients were node 
negative, pregnancy/lactation-associated breast cancer 
was found in 29.8% (n = 36). Left side involvement was 
seen in 53.7% (n = 65); only a single patient had bilateral 
disease at the time of presentation. Most patients presented 
in Stages III and II disease, 52.1% (n = 63) and 33.9% 
(n = 41), respectively, 10% (n = 13) of patients presented 
with Stage IV disease. Most common histological subtype 
was invasive ductal carcinoma, found in 94.2% (n = 114), 
other less common types were mucinous, invasive lobular, 
malignant phyllodes and ductal carcinoma in situ. Triple 
negative was the most common luminal subtype present in 
46.3%% (n = 56), followed by luminal A 29.8% (n = 36) 
and luminal B 16.5% (n = 20), her-2 neu overexpression 
was seen in 7.4% (n = 9) patients.
Almost half of the patients 49.6% (n = 60) received 
neoadjuvant chemotherapy. CR was observed in 
20% (n = 12) while 66.6% (n = 40) had PR and 5 patients 
showed NR to first-line chemotherapy.
Modified radical mastectomy was performed in 57% 
(n = 69), while 35.5% (n = 43) underwent breast 
conservation surgery, nine patients were not candidates 
for surgery as they had progressive Stage IV disease. 
52 patients received chemotherapy in the adjuvant setting. 
Most of our patients 88.4% (n = 107) did receive radiation 
Table 1: Demographic characteristics
Characteristics Frequency % (n)
Age group
20–25 years 18.1 (22)














Invasive ductal carcinoma 94.2 (114)
Mucinous carcinoma 2.47 (3)
Malignant haloids 0.8 (1)
Invasive lobular carcinoma 1.65 (2)
Ductal carcinoma in situ 0.8 (1)
Molecular subtypes
Luminal A 29.8 (36)
Luminal B 16.5 (20)
Triple negative 46.3 (56)
Her 2 neu type 7.4 (9)
Stage
Stage O 3.3 (4)
Stage I 0.8 (1)
Stage II 33.9 (41)
Stage III 52.1 (63)
Stage IV 9.1 (11)
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therapy. Hormonal treatment in the form of tamoxifen 
was received by 45.5% (n = 55) of patients, targeted 
therapy in the form of trastuzumab was received by four 
patients only [Table 2]. Local relapse occurred in 12.4% 
(n = 15), while 33.8% (n = 41) developed distant relapse, 
17.4% (n = 21) patients developed brain metastasis. After 
5 years only 57.9% (n = 70) were alive, cancer related 
deaths were 42.1% (n = 51). 5 years OS was 57.9%. 
5 years survival according to the stage at presentation is 
shown in Figure 1.
Discussion
Breast cancer in women of age 35 is different from 
breast cancer occurring at an older age (>40 years), it 
has aggressive tumour biology, high proliferative index, 
higher tumour grade, lack of oestrogen receptors and 
progesterone positivity, usually are poorly differentiated 
and carry poorer survival as compared to the older 
population.[9] Most of our patients had invasive ductal 
carcinoma grade two or three, 46.3% of our patients were 
triple negative.
Due to the lack of screening programs in the developing 
countries presentation is often delayed,[10] almost half of 
our patients (50.4%) were locally advanced at presentation. 
Due to unfavourable tumour biology younger women has 
low survival as compared to the elderly.[11] 5 years OS in 
our study population was 57.9%.
The mean age at diagnosis is much younger in Asian 
countries as compared to western; the incidence is 
increasing with the passage of time.[12] Pregnancy-
associated breast cancer (PABC) is defined as breast 
cancer arising in pregnant women or lactation, 1 year 
after the delivery,[13] it carries poorer prognosis due to 
delay in diagnosis as breast size increase and denser. 
PABC is very aggressive with her-2 neu overexpression, 
or triple negative with higher proliferative index.[14] The 
interactions between pregnancy and breast cancer are 
complex and variable, may be increased hormonal levels 
promote proliferation of existing tumours,[15] 29.8% of our 
patients presented with pregnancy or lactation-associated 
breast cancer, all presented with larger tumour size. Risk 
of breast cancer becomes 2 times in patients with family 
history of breast cancer, however, for PABC, the risk 
remains the same as for non PABC tumours according to 
Johansson et al.[16] 11.6% of our patients have a positive 
family history of first-degree relative.
Triple negative breast cancer is an independent poor 
prognostic factor, this molecular subtype is more common 
Table 2: Treatment details




Modified radical mastectomy 57 (69)
Breast conservation surgery 35.5 (43)
No surgery 7.4 (9)
Radiation to breast
Received 88.4 (107)
Not received 11.6 (14)
Hormonal Treatment
Received 45.5 (55)
Not received 54.5 (66)




Distant relapse 33.8 (41)




Figure 1: Kaplan–Meier showing 5 years overall survival 
according to stage
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in the younger age group, therefore, two worst things 
combine together, risk of death becomes 2.7-folds when 
triple negative cancer arise in younger population,[17] 
46.3% of our patients were triple negative and only nine 
patients showed her-2 neu overexpression. Tang et al. 
carried out a retrospective review of 1360 Chinese women 
<40 years of age and studied the relationship between 
luminal B subtype and prognosis; they found increased 
risk of local recurrence and increase death risk in these 
patients.[18] Younger patients also show a higher proportion 
of BRCA1 and BRCA 2 mutations.[19]
Chemotherapy is the mainstay of treatment in invasive 
breast cancer, to achieve local as well as systemic 
control, inpatient with locally advanced disease, 
lymph node-positive patients and to downstage 
tumour size in patients who are candidates for breast 
conservation.[20] Women who are <30 years who do not 
receive chemotherapy are at high risk of local and distant 
relapse. 60 patients in our study received neoadjuvant 
chemotherapy while 52 patients received chemotherapy 
after surgery.
Nearly 57% of our patients underwent modified radical 
mastectomy, while 35.5% underwent breast conservation 
surgery, Cao et al. compared local recurrence and survival 
rate in younger patients undergoing breast conservation 
or mastectomy and they observed that mastectomy 
offers no additional survival benefits compared to breast 
conservation.[21] According to Bleyer et al. younger 
women carries poorer survival in all stages of the disease 
when compared to older women,[22] they compared women 
age groups; 20–35 and 45–75 years old and for all the 
stages younger patients had decreased OS as compared 
to older patients.
Many studies have shown that age itself is a risk factor 
for poor prognosis, Brandit et al. studied age at diagnosis 
in relation to the survival in 4453 women of different 
age groups and observed that after follow-up period of 
10 years women of age group <40 years with axillary 
lymph node-negative disease had poorer outcome.[23] We 
also found a higher mortality rate in our population despite 
aggressive treatment. Andres et al. concluded that younger 
age at the time of diagnosis carries poorer prognosis.[24] 
Assi et al. described breast cancer in younger age as 
very aggressive tumours with poor prognostic factors 
and higher recurrence rate and distant relapse leading to 
worst prognosis.[25]
Conclusions
The incidence of breast cancer in very young females 
(<30) is increasing over the years, tumour biology in this 
age group is aggressive, with poorer prognostic factors. 
Since half of our patients presented with advanced stage; 
therefore, we emphasize the need to increase awareness 
among the younger population to achieve better disease 
control.
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